# Contents

## Behavioral Pharmacology

Novel Antimuscarinic Antidepressant-like Compounds with Reduced Effects on Cognition  
**Chad R. Johnson, Brian D. Kangas, Emily M. Jutkiewicz, Gail Winger, Jack Bergman, Andrew Coop, and James H. Woods**

## Cardiovascular

Chronic Ca²⁺/Calmodulin-Dependent Protein Kinase II Inhibition Rescues Advanced Heart Failure  
**Yixi Liu, Qun Shao, Heng-Jie Cheng, Tiankai Li, Xiaowei Zhang, Michael F. Callahan, David Herrington, Dalane Kitzman, David Zhao, and Che-Ping Cheng**

Therapeutic Assessment of Combination Therapy with a Neprilysin Inhibitor and Angiotensin Type 1 Receptor Antagonist on Angiotensin II–Induced Atherosclerosis, Abdominal Aortic Aneurysms, and Hypertension  
**Yasir AlSiraj, Sean E. Thatcher, Ching Ling Liang, Heba Ali, Mark Ensor, and Lisa A. Cassis**

## Cellular and Molecular

circ-Keratin 6c Promotes Malignant Progression and Immune Evasion of Colorectal Cancer through microRNA-485-3p/Programmed Cell Death Receptor Ligand 1 Axis  
**Zhipeng Jiang, Zehui Hou, Wei Liu, Zhuomin Yu, Zhiqiang Liang, and Shuang Chen**

Poly(ADP-Ribose) Polymerase Inhibitors for Arsenic Trioxide–Resistant Acute Promyelocytic Leukemia: Synergistic In Vitro Antitumor Effects with Hypomethylating Agents or High-Dose Vitamin C  
**Manuela Giannisanti, Antonio De Gabrieli, Salvatore Pasquale Prete, Tiziana Ottone, Maria Domenica Divona, Terry Karimi, Fabio Ciccarone, Maria Teresa Voso, Grazia Graziani, and Isabella Faraoni**

## Chemotherapy, Antibiotics, and Gene Therapy

Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation  
**Qingxiang Lin, Zhicheng Qian, William J. Jusko, Donald E. Mager, Wen Wee Ma, and Robert M. Straubinger**

## Drug Discovery and Translational Medicine

A Novel Integrated Pharmacokinetic-Pharmacodynamic Model to Evaluate Combination Therapy and Determine In Vivo Synergism  
**Young Hee Choi, Chao Zhang, Zhenzhen Liu, Mei-Juan Tu, Ai-Xi Yu, and Ai-Ming Yu**

AM833 Is a Novel Agonist of Calcitonin Family G Protein–Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists  
**Madeleine M. Fletcher, Peter Keov, Tin T. Truong, Grace Mennen, Caroline A. Hick, Peishen Zhao, Sebastian G.B. Furness, Thomas Kruse, Trine R. Clausen, Denise Wootten, and Patrick M. Sexton**

## Endocrine and Diabetes

Ginsenoside Ro Ameliorates High-Fat Diet–Induced Obesity and Insulin Resistance in Mice via Activation of the G Protein–Coupled Bile Acid Receptor 5 Pathway  
**Lin-shan Jiang, Wei Li, Tong-xi Zhuang, Jie-jing Yu, Shuai Sun, Zheng-cai Ju, Zheng-tao Wang, Li-li Ding, and Li Yang**
GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Characterization of Novel Fluorescent Bile Salt Derivatives for Studying Human Bile Salt and Organic Anion Transporters
Michele Leuenberger, Stephanie Häusler, Vera Höhn, Adriana Euler, Bruno Stieger, and Martin Lochner

NEUROPHARMACOLOGY

Brain Concentrations of Methylone and Its Metabolites after Systemic Methylone Administration: Relationship to Pharmacodynamic Effects
Nicole Centazzo, Michael R. Chojnacki, Joshua S. Elmore, Raider Rodriguez, Teeshavi Acosta, Masaki Suzuki, Kenner C. Rice, Michael H. Baumann, and Marta Concheiro

Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease

LETTER TO THE EDITOR

Comments on “Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist for the Treatment of Short Bowel Syndrome”
Jolanta Skarbaliene, Bjarne Due Larsen, Mark Berner-Hansen, and Adam Steensberg

ERRATUM

Correction to “Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome”

Supplemental material is available at jpet.aspetjournals.org.

About the cover: A new PK/PD model and strategy to evaluate combination therapy and define in vivo synergism. See the article by Choi et al. (dx.doi.org/10.1124/jpet.121.000584).